Vitamin Shoppe, Inc (NYSE:VSI) – Investment analysts at Gabelli cut their FY2017 earnings per share (EPS) estimates for shares of Vitamin Shoppe in a research note issued on Thursday. Gabelli analyst D. Witkowski now anticipates that the specialty retailer will post earnings of $0.40 per share for the year, down from their previous estimate of $0.75. Gabelli also issued estimates for Vitamin Shoppe’s FY2018 earnings at $0.25 EPS, FY2019 earnings at $0.40 EPS and FY2020 earnings at $0.75 EPS.
Vitamin Shoppe (NYSE:VSI) last announced its earnings results on Wednesday, November 8th. The specialty retailer reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.20). The business had revenue of $288.20 million for the quarter, compared to analyst estimates of $297.61 million. Vitamin Shoppe had a positive return on equity of 6.17% and a negative net margin of 20.27%. The business’s revenue was down 8.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.50 EPS.
A number of other equities analysts have also weighed in on the stock. Goldman Sachs Group, Inc. (The) reissued a “sell” rating and issued a $6.00 price objective (down previously from $13.00) on shares of Vitamin Shoppe in a research report on Thursday, August 10th. Barclays PLC cut their price objective on shares of Vitamin Shoppe from $6.00 to $3.00 and set an “equal weight” rating for the company in a research report on Thursday, November 9th. Deutsche Bank AG reissued a “hold” rating and issued a $7.00 price objective (down previously from $14.00) on shares of Vitamin Shoppe in a research report on Thursday, August 10th. TheStreet lowered shares of Vitamin Shoppe from a “c-” rating to a “d” rating in a research report on Wednesday, August 9th. Finally, Morgan Stanley cut their price objective on shares of Vitamin Shoppe from $7.50 to $4.00 and set an “equal weight” rating for the company in a research report on Thursday, November 9th. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $5.00.
Vitamin Shoppe (NYSE:VSI) opened at $3.60 on Monday. The company has a current ratio of 2.07, a quick ratio of 0.32 and a debt-to-equity ratio of 0.59. The stock has a market cap of $83.92, a PE ratio of 3.76 and a beta of 0.74. Vitamin Shoppe has a 52-week low of $2.95 and a 52-week high of $26.35.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. grew its stake in Vitamin Shoppe by 34.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 262,123 shares of the specialty retailer’s stock worth $3,054,000 after buying an additional 67,362 shares during the period. Aperio Group LLC acquired a new position in shares of Vitamin Shoppe during the second quarter worth $402,000. Teachers Advisors LLC lifted its position in shares of Vitamin Shoppe by 4.7% during the first quarter. Teachers Advisors LLC now owns 63,691 shares of the specialty retailer’s stock worth $1,283,000 after purchasing an additional 2,887 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Vitamin Shoppe by 88.5% during the second quarter. Goldman Sachs Group Inc. now owns 124,077 shares of the specialty retailer’s stock worth $1,445,000 after purchasing an additional 58,243 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of Vitamin Shoppe by 16.7% during the second quarter. Russell Investments Group Ltd. now owns 26,788 shares of the specialty retailer’s stock worth $312,000 after purchasing an additional 3,839 shares in the last quarter. Institutional investors own 98.39% of the company’s stock.
In related news, Director John D. Bowlin bought 40,000 shares of the stock in a transaction that occurred on Friday, August 25th. The stock was purchased at an average cost of $5.50 per share, for a total transaction of $220,000.00. Following the completion of the acquisition, the director now owns 56,028 shares in the company, valued at $308,154. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.07% of the stock is currently owned by insiders.
About Vitamin Shoppe
Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.
Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with MarketBeat.com's FREE daily email newsletter.